Patients with suspected new bladder cancer were randomly assigned 1:1 to transurethral resection of bladder tumor or mpMRI-staged care.

Pembrolizumab monotherapy showed antitumour activity and manageable toxicity in patients with BCG-unresponsive high-risk Ta or T1 bladder cancer without carcinoma in situ and could potentially be a ...

Multiple novel treatment approaches are currently available for urothelial cancer. What's needed now are well-designed, prospective clinical trials with standardized endpoints to identify the ...

WEDNESDAY, Oct. 18, 2023 (HealthDay News) — For patients with non-muscle-invasive bladder cancer (NMIBC), selenium supplementation does not reduce the risk for recurrence, while vitamin E is ...

For patients with non-muscle-invasive bladder cancer (NMIBC), selenium supplementation does not reduce the risk for recurrence, while vitamin E is associated with an increased risk for recurrence ...

There is a significant unmet need for new and efficacious therapies in urothelial cancer (UC). To provide recommendations on appropriate clinical trial designs across disease settings in UC, the ...

DaBlaCa-13 Study: Oncological Outcome of Short-Term, Intensive Chemoresection With Mitomycin in Nonmuscle Invasive Bladder Cancer: Primary Outcome of a Randomized Controlled Trial ...